Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1

NCT02310243 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT02310243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02310243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1
Lead sponsor
University of Ulm
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2015
Completion date
July 31, 2019
Enrollment
50 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia